小分子TRK抗体:我们从这里走到哪里?
Tye S Thompson1, Arthur Sefiani2, Kevin Burgess1
1Department of Chemistry, Texas A&M University, Box 30012, College Station, Texas 77842-3012, United States.
研究人员探索了Trk (热氨酸受体激酶) 的小分子调节器,以治疗神经退行和损伤. 在查中优先考虑现有药物加速了发现,但面临限制,影响了当前的发展.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 20年前,TRK (热氨酸受体激酶) 调节器还没有出现.
- 特克在神经退行和创伤方面的潜力刺激了研究.
- 高通量选 (HTS) 提供了一条识别调制器的途径.
研究的目的:
- 审查通过HTS识别Trk调节器的历史努力.
- 讨论从过去的药物发现策略中吸取的教训.
- 为了识别阻碍Trk调制器开发的当前限制.
主要方法:
- 审查过去的Trk调制器高通量选活动.
- 分析过标准,包括对现有药物的优先考虑.
- 检查图书馆选中的成本和努力限制.
主要成果:
- 商业图书馆的HTS发现了潜在的Trk调制器.
- 优先考虑现有药物提供已知的安全性和BBB透性数据.
- 由于成本和努力影响复合数量的选限制.
结论:
- 过去的HTS努力为Trk调制器的发现提供了宝贵的见解.
- 学到的经验教训强调了战略性图书馆过的重要性.
- 目前的发展受到本次审查中确定的因素的限制.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
12:09Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
Published on: December 31, 2013
相关概念视频
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies
There are several types of targeted therapies against...
